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Abstract
Background: This study was undertaken to provide pharmacological basis for the medicinal use of Viola odorata
Linn. in hypertension and dyslipidemia using the in vivo and in vitro assays.
Results: Viola odorata leaves extract (Vo.Cr), which tested positive for alkaloids, saponins, tannins, phenolics,
coumarins and flavonoids, caused a dose-dependent (0.1-1.0 mg/kg) decrease in mean arterial blood pressure in
anaesthetized rats. In isolated guinea-pig atria, Vo.Cr equally inhibited force and rate of spontaneous atrial
contractions. On the baseline of rat thoracic aortae (endothelium-intact and denuded), the plant extract caused
phentolamine-sensitive vasoconstriction. When tested on phenylephrine (PE, 1 μM) and K+ (80 mM)-induced
vasoconstriction, Vo.Cr caused a concentration-dependent relaxation and also caused a rightward shift of Ca++
concentration-response curves as well as suppression of PE (1 μM) control peaks in Ca++-free medium, similar to
that caused by verapamil. In the presence of L-NAME, the relaxation curve of Vo.Cr was partially inhibited showing
involvement of Nitric oxide (NO) mediated pathway. In Tyloxapol-induced dyslipidemia, Vo.Cr caused reduction in
total cholesterol and triglyceride levels. In high-fat diet-induced dyslipidemia model, the plant extract caused a
significant decrease in total cholesterol, LDL-C, atherogenic index and prevented the increase in average body
weights, while it increased HDL-C.
Conclusions: These data indicate that the vasodilator effect of the plant extract is mediated through multiple
pathways like inhibition of Ca++ influx via membranous Ca++ channels, its release from intracellular stores and NO-
mediated pathways, which possibly explain the fall in BP. The plant also showed reduction in body weight and
antidyslipidemic effect which may be due to the inhibition of synthesis and absorption of lipids and antioxidant
activities. Thus, this study provides a pharmacologic rationale to the medicinal use of Viola odorata in hypertension
and dyslipidemia.
Keywords: Viola odorata leaves, antihypertensive, antidyslipidemic, Ca++ antagonist, NO-mediated.
Background
Hypertension and dyslipidemia, major risk factors for
coronary heart disease [1], are interrelated. The overall
dyslipidemia can contribute to a chronic increase in vas-
cular tone resulting in hypertension [2]. In order to
reduce cardiovascular risk, it is important to regulate
hypertension as well as dyslipidemia [3].
The modern pharmacological therapy is costly and
associated with multiple side effects resulting in patient
non-compliance. Thus there is a need to explore alter-
native therapies particularly from herbal sources as
these are cost effective and possess minimal side-
effects.
Viola odorata Linn., commonly known as sweet violet
in English, belongs to the family Violaceae. It is called
Banafsha in Indo-Pakistan [4]. The plant is native to
Asia, North Africa and Europe. In Pakistan, Viola odor-
ata is found in the northern areas, such as Nathia gali,
Hazara, Kaghan, Swat and Chitral at the height of 1500-
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2000 meters [5]. Its history as a medicinal herb dates
back as far as 500 BC, where it was known to be used
to relieve pain due to cancer [6]. In the traditional sys-
tem, it has been used in anxiety [7], insomnia and to
lower blood pressure [8].
Viola odorata contains alkaloid, glycoside, saponins,
methyl slicylate, mucilage and vitamin C [9]. The plant
has been reported to possess antioxidant [10] and diure-
tic [11] activities along with other beneficial effects but
no study has been found regarding its blood pressure
lowering or lipid-lowering activity. In present investiga-
tion, we report the antihypertensive and antidyslipi-
demic effects of Viola odorata along with possible
mechanisms.
Materials and methods
Plant material and Extraction procedure
Dried leaves of Viola odorata were purchased from
“Insaf kiryana store” Daryalal street, Jodia bazaar, Kara-
chi, Pakistan. A sample of the plant material was depos-
ited in the Natural Products Research Division,
Department of Biological and Biomedical Sciences, The
Aga Khan University, Karachi, Pakistan with voucher
number VO-LF-06-10-107. The leaves, after cleaning of
adulterants, weighed 1.3 kg, were soaked in 14 L of aqu-
eous-methanol (30:70) for a total of 3 days with occa-
sional shaking. The plant material was filtered through a
muslin cloth and then through a Whatman qualitative
grade-1 filter paper. This procedure was repeated twice
and the combined filtrate was concentrated in a rotary
evaporator at 35-40°C under reduced pressure to obtain
a thick, dark brown extract (Vo.Cr) with a yield of 21%
(w/w). Vo.Cr was completely solubilized both in distilled
water and saline for use in the in vitro and in vivo
experiments.
Drugs and standards
Acetylcholine chloride, Nω-nitro-L-arginine methyl ester
hydrochloride (L-NAME), cholesterol, cholic acid, phe-
nylephrine, phentolamine hydrochloride, norepinephr-
ine, verapamil hydrochloride, potassium chloride and
tyloxapol of reagent grade were purchased from Sigma
Aldrich Chemical Company (St Louis, MO, USA). Ran-
dox diagnostic kits for serum analyses were purchased
from Randox Laboratories (Antrim, UK). The butter fat
used was in the form of “Asli desi ghee” manufactured
by Haleeb food industries, Pakistan purchased from a
local bakery in Karachi, Pakistan. All chemicals used
were of the highest purity grade. Physiological salt solu-
tions were prepared fresh in distilled water on the day
of each experiment, whereas stock solutions of all the
drugs and extract were prepared in distilled water or
saline and the dilutions were prepared fresh on the day
of each experiment.
Animals
Animals used in this study, Sprague-Dawley (SD) rats
(180-200 g), Balb-C mice (20-25 g) and guinea-pigs
(450-500 g) of either sex or local breed were housed at
the Aga Khan University animal house under a con-
trolled environment (23-25°C) with free access to food
and water. All experiments performed complied with
the rulings of the Institute of Laboratory Animal
Resources, Commission on Life Sciences, National
Research Council [12].
Preparation of diets
The following two types of diet were prepared:
A. Normal diet: The normal diet was prepared as
described previously by Harkness and Wagner [13] at
the animal house of the Aga Khan University, Karachi.
The standard diet consisted of flour (5 kg), chokar (5
kg), molasses (150 g), salt (75 g), nutrivet-L (33 g),
potassium metabisulfite (15 g), oil (500 g), fishmeal
(2.25 kg) and powdered milk (2 kg), comprising a total
mass of about 15 kg of food material.
B. Atherogenic diet: Cholesterol (2% w/w), cholic acid
(0.5% w/w) and butter fat (5% w/w) were added to the
normal diet, as described by Ichihashi [14], with slight
modifications.
All measures were taken to ensure the uniform mixing
of additives in dry ingredients of the diet before
kneading.
Phytochemical screening
Preliminary screening of the plant extract for various
phytochemical classes was carried out based on a modi-
fied version of the reported methods [15]. The crude
extract was screened for the presence of saponins, flavo-
noids, tannins, phenols, coumarins, sterols, terpenes,
alkaloids and anthraquinones.
In vivo blood pressure measurement in anaesthetized rats
These experiments were performed on male Sprague-
Dawley (SD) rats (200-250 g) as described previously
[16]. The animals were anaesthetized with an intra-peri-
toneal (i.p.) injection of sodium thiopental (Pentothal,
70-90 mg/kg body weight), and arterial blood pressure
was recorded through carotid artery cannulation by a
pressure transducer (MLT1199) coupled to a Bridge
Amplifier and PowerLab 4/25 (ADInstruments). Drugs
were injected through a cannula inserted into the jugu-
lar vein. After a 20-min period of equilibration equili-
brium, the rats were injected intravenously with 0.1 ml
saline (0.9% NaCl) or with the same volume of test sub-
stance. Arterial pressure was allowed to return to the
resting level between injections. Control responses of
standards, such as acetylcholine (1 mg/kg) and norepi-
nephrine (1 mg/kg), were obtained before the extracts
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were tested. Changes in mean arterial pressure (MAP)
were recognized as the difference between the steady-
state value before and the lowest reading after injection.
MAP was calculated as the sum of the diastolic pressure
(DP) and one-third of the pulse pressure (PP), where PP
= SP-DP (SP = systolic pressure).
Isolated tissue experiments
Guinea-pig atria
Guinea-pigs were sacrificed by cervical dislocation; right
atria were dissected out carefully, cleaned of fatty tissue
and mounted individually in 20 ml tissue baths contain-
ing Kreb’s solution at 32°C and aerated with carbogen
(5% CO2 in O2) [17]. The composition of the Kreb’s
solution was (mM): NaCl 118.2, NaHCO3 25.0, CaCl2
2.5, KCl 4.7, KH2PO4 1.3, MgSO4 1.2 and glucose 11.7
(pH 7.4). The tissues were allowed to beat sponta-
neously (due to the presence of pacemaker cells) under
the resting tension of 1 g. An equilibrium period of 30
min was given before the application of any drug. Con-
trol responses of isoproterenol (1 μM) and of acetylcho-
line (1 μM) were obtained. Tension changes in the
tissue were recorded via force-displacement transducer
(model FT-03) using Grass Model 7 Polygraph.
Rat aorta preparation
The procedure of Furchgott and Zawadski [18] was fol-
lowed with some modifications. Thoracic aorta was iso-
lated from the rat and cut into rings, which were
mounted individually in 5 ml of tissue bath, maintained
at 37°C and aerated with carbogen. A preload of 1 g was
applied to each preparation and incubated for 60 min.
Changes in isometric tension were recorded and ana-
lyzed through a force transducer (model FORT100)
coupled to a Trans-bridge (model TBM4M, World Preci-
sion Instruments, Hertfordshire, UK), a PowerLab data
acquisition system (model ML845, ADInstruments) and
a computer running the Chart software (version 5.3).
The tissues were then stabilized with phenylepherine
(PE 1 μM). After stabilization, an induced contraction
was obtained with PE. Once plateau was achieved, acet-
ylcholine (ACh 0.3 μM) was tested on PE-induced con-
traction to observe the endothelium integrity. The
endothelium lining of some tissues was removed by gen-
tle rubbing, which resulted in the disappearance of the
relaxation caused by ACh. To study whether or not the
vasodilator effect of the test substance is endothelium-
dependent, the PE-induced contraction was pre-incu-
bated with L-NAME (0.1 mM) for 20 min to explore
the possible mode of endothelium-dependent vasodilator
action [19].
High K+ (80 mM) was also used to produce sustained
contraction. The inhibition of PE and high K+ -induced
sustained contractions would indicate a blockade of Ca+
+ influx through membrane bound receptor-operated
and voltage-dependent Ca++ channels respectively [20].
The plant material was then tested against PE-evoked
peaks in the Ca++-free Kreb’s solution to observe its
effect on the intracellular stores. In the Ca++-free med-
ium, PE acts through stimulation of a1-adrenergic
receptors and then the consequent conversion of phos-
phatidylinositol to inositol-1, 4, 5-triphosphate which
releases Ca++ from the sarcoplasmic reticulum resulting
in a tonic contraction [21].
To confirm the calcium channel blocking (CCB) activ-
ity, Ca++ concentration-response curves (CRCs) were
constructed in a Ca++ free medium. Subsequently, the
effect of increasing concentration of the extract was
determined on the Ca++ CRCs. A shift in the Ca++
curves to the right would confirm CCB.
Some experiments were performed on the resting
baseline of the endothelium intact as well as denuded
preparations. The tissues were stabilized with PE. At a
steady-state baseline, the vasoconstrictor effect of Vo.Cr
was evaluated and expressed as percent of PE-induced
contraction.
Antidyslipidemic activities
Tyloxapol-induced dyslipidemia
The tyloxapol-induced dyslipidemic model [22] was fol-
lowed with slight modifications. Male SD rats weighing
160-180 g were randomly divided into six groups (n = 6
each). All groups were fed normal diet. Group 3-6 were
given treatment by oral gavage for ten days. Group 3
received atorvastatin 10 mg/kg; group 4 received Vo.Cr
150 mg/kg; group 5 received Vo.Cr 300 mg/kg and
group 6 received Vo.Cr 600 mg/kg; all dissolved in
drinking water. After 10 days of the treatment, all ani-
mals were fasted for 7 h and group 1 received saline (10
ml/kg; i.p.) whereas all other groups were administered
tyloxapol (500 mg/kg; i.p.). On the following day, all ani-
mals were anaesthetized by diethyl ether (by inhalation),
and the blood was collected for analysis of serum total
cholesterol (TC) and triglycerides (TGs).
High-fat diet induced dyslipidemia
The effect of Vo.Cr on high fat diet-induced dyslipide-
mia was studied using the method described by Ber-
roughui [23] with slight modifications introduced after
pilot studies. Adult SD rats (12-14 weeks old, weighing
140-160 g) were randomly divided into five groups (7-10
in each). Group 1 was fed diet A (served as normal con-
trol) while all other groups were fed diet B (atherogenic
diet). Group 2 served as dyslipidemic control. Groups 3-
5 were given treatment by oral gavage for six weeks.
Group 3 received atorvastatin 10 mg/kg; group 4
received Vo.Cr 300 mg/kg and group 5 received Vo.Cr
600 mg/kg; all dissolved in drinking water. Animals in
all groups had free access to water and food. Diet con-
sumption was monitored daily, and the gain in body
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weight was monitored weekly. At the end of 6 weeks of
treatment, animals were fasted for 16 h before blood
collection, and samples were analyzed for serum lipids
and glucose levels.
Biochemical studies
Estimation of lipid profile and glucose level
The blood was collected in vacuutainer by cardiac punc-
ture from fasting anaesthetized rats. The serum was sepa-
rated after centrifugation at 3000 rpm for 10 min. The
serum lipids and glucose were assayed enzymatically using
commercially available kits. Methods described by the
manufacturer (Randox Laboratories Ltd., Co. Antrim,
UK.) were used for the determination of serum total cho-
lesterol (TC), high density lipoprotein (HDL), triglyceride
(TG) and glucose. Low-density lipoproteins (LDL) were
estimated indirectly by using formula: LDL = TC-HDL-
TG/5. Atherogenic index was calculated using formula:
Atherogenic index = TC-HDL/HDL [24].
Acute toxicity assessment
Vo.Cr was evaluated for acute toxicity using Balb-C
mice as described earlier by Gilani [25]. The mice were
divided into four groups of six mice in each group and
were given increasing doses of Vo.Cr extract (1, 3 and 5
g/kg) in 10 ml/kg volume orally. A negative control
group was administered saline (10 ml/kg). All the mice
were allowed food and water ad libitum and were kept
under regular observation for mortality and gross beha-
vioural changes such as activity in home cage, apathy
and aggression for 48 h.
Statistical analysis
All data were expressed as means ± standard error of
mean (SEM, n = number of experiments) and the median
effective concentration (EC50) values were calculated as
the geometric mean with 95% confidence intervals (CI).
The statistical parameter applied was student’s t-test.
CRCs were analyzed by nonlinear regression. One-way
analysis of variance (one-way ANOVA) followed by
Tukey’s post-test was used to determine significant differ-
ences in various biological parameters with and without
treatment. Two-way ANOVA followed by Bonferroni’s
post-test correction was used for multiple comparisons of
CRCs with control. P-values < 0.05 were considered signif-
icant. All the graphing, calculations and statistical analyses
were performed using GraphPad Prism software version
4.00 for Windows, (GraphPad Software, San Diego, CA,
USA, http://www.graphpad.com).
Results
Phytochemical screening
The phytochemical analysis of the crude extract of Viola
odorata (Vo.Cr) showed the presence of alkaloids, sapo-
nins, tannins, phenolics, coumarins and flavonoids.
Effect on blood pressure of anaesthetized rats
Vo.Cr at 0.1, 0.3 and 1.0 mg/kg induced a percent
fall of 15.40 ± 1.43, 27.80 ± 2.37 and 48.60 ± 3.35
(mean ± SEM, n = 5), respectively in mean arterial
pressure (MAP) of rats under anaesthesia as shown
in Figure 1.
Effect on guinea-pig atria
In the isolated guinea-pig atrium, the plant extract
depressed the force and rate of spontaneous contracting
atria with respective EC50 values of 0.39 (0.21-0.75, 95%
CI; n = 3) and 0.40 mg/ml (0.12-1.38; n = 3) as seen in
Figure 2A, similar to verapamil which inhibited the
force and rate of atrial contraction with respective EC50
values of 0.59 (0.47-0.75; n = 6) and 0.94 μM (0.68-1.30;
n = 6) (Figure 2B).
Effect on isolated rat aorta preparations
Effect on baseline tension
When tested on resting tension of endothelium-intact
tissue, Vo.Cr caused a concentration-dependent (0.03-
3.0 mg/ml) vasoconstriction with maximum of 46.4 ±
2.8% (n = 4) of PE (1 μM) maximum contraction (Fig-
ure 3A) followed by complete relaxation at the next
higher concentration of 5 mg/ml. In denuded tissues,
Vo.Cr also induced vasoconstriction with resultant
maximum contraction of 82.6 ± 2.6% (n = 4) at 3 mg/
kg (Figure 3A) followed by partial relaxation at the
dose of 5 mg/ml. When the vasoconstrictor effect of
Vo.Cr in intact tissues was reproduced in the presence
of L-NAME (0.1 mM), it was enhanced as 79.6 ± 2.9%
(n = 4) vs 46.4 ± 2.8% (n = 4) (Figure 3A), while the
vasodilator effect was partially inhibited at the higher
tested concentration of 5 mg/ml. The vasoconstrictor
effect of Vo.Cr, in intact and denuded tissues, was
completely blocked when repeated in the presence of
phentolamine (1 μM) (data not shown), while verapa-
mil was devoid of any stimulatory effect on the base-
line in either tissue (Figure 3B).
Endothelium-dependent and independent effects
Vo.Cr caused a concentration-dependent relaxation of
PE (1 μM)-induced contractions in endothelium-intact
and denuded rat aortic preparations with respective
EC50 values of 4.98 (3.93-6.30; n = 5) and 10.54 mg/ml
(9.10-12.21; n = 4). When the relaxant effect of Vo.Cr
was reproduced in intact aortic rings in the presence of
L-NAME (0.1 mM), the relaxation curve was partially
inhibited with resultant EC50 value of 10.11 mg/ml
(6.61-15.43; n = 4) vs 4.98 (3.93-6.30; n = 5). When
tested on high K+ (80 mM)-induced contraction, Vo.Cr
caused relaxation with EC50 value of 4.38 mg/ml (3.87-
4.95; n = 7) as shown in Figure 3A. Verapamil also
inhibited PE-induced contractions in endothelium-intact
Siddiqi et al. Lipids in Health and Disease 2012, 11:6
http://www.lipidworld.com/content/11/1/6
Page 4 of 12
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
0.1 0.3 1.0 
0
10
20
30
40
50
60
*
***
(B)
[Vo.Cr] mg/kg
%
 o
f  
fa
ll 
in
 M
A
P
Figure 1 (A) Tracing from a typical experiment showing the effect of increasing doses of crude extract of Viola odorata (Vo.Cr) on
mean arterial blood pressure (MAP) of an anaesthetized rat. Small triangles indicate the times at which the drugs were administered. (B)
Bar chart represents combined effect (mean ± SEM) of 5 experiments. * P < 0.05; *** P < 0.001 (One way ANOVA followed by Tukey’s multiple
comparison).
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and denuded rat aortic preparations at similar concen-
trations with respective EC50 values of 0.41 (0.25-0.66; n
= 3) and 0.71 μM (0.40-1.26; n = 3), while it inhibited
high K+-induced contractions with EC50 value of 0.18
μM (0.13-0.26; n = 4) (Figure 3B).
Determination of calcium channel blocking (CCB) activity
Pretreatment of rat aortic rings with Vo.Cr caused a
concentration-dependent (0.03-0.1 mg/ml) rightward
shift in the Ca++ concentration-response curves con-
structed in Ca++- free medium, similar to that caused by
verapamil at 0.01-0.03 μM (Figure 3).
Effect on intracellular Ca++ stores
Vo.Cr (0.03-0.3) mg/ml and verapamil (0.03-0.3) μM
suppressed PE (1 μM) peak responses in Ca++ free
Kreb’s solution in a concentration-dependent manner as
shown in Figure 4.
Antidyslipidemic activities
Effects on tyloxapol-induced dyslipidemia
Treatment of animals with Tyloxapol (Triton WR-1339)
caused an increase in serum total cholesterol and trigly-
cerides compared to normal controls. Pretreatment of
the rats with Vo.Cr at 300 and 600 mg/kg protected
against tyloxapol-induced hypercholesterolemia and
hypertriglyceridemia similar to atorvastatin (10 mg/kg)
as shown in Table 1.
Effects on high fat diet-induced dyslipidemia
Atherogenic diet significantly increased the serum total
cholesterol (TC), low density lipoprotein-cholesterol
(LDL-C) and atherogenic index, while it decreased high
density lipoprotein-cholesterol (HDL-C) as compared to
control. Supplementation of atherogenic diet with Vo.Cr
(600 mg/kg) and atorvastatin (10 mg/kg) prevented the
rise of mean serum TC, LDL-C and atherogenic index.
Both the treatments significantly increased HDL-C com-
pared to atherogenic control group. However, there was
no effect seen on serum triglycerides and glucose levels.
The decrease in body weight was accompanied by slight
reduction in daily diet consumption. The data are sum-
marized in Table 2.
Acute toxicity assessment
For acute toxicity study, mice were divided into four
groups. First group received normal saline (10 ml/kg)
while the other three groups were administered graded
doses of 1, 3 and 5 g/kg of Vo.Cr, respectively. All ani-
mals showed usual activity in home cages and no mor-
tality or gross behavioural changes such as apathy or
aggression were observed for 48 h.
Discussion
The aqueous-methanolic extract of Viola odorata caused
a dose-dependent fall in blood pressure of rats under
anaesthesia, which is in accordance with its medicinal
use in hypertension [7]. Blood pressure is the product of
cardiac output and peripheral resistance [26], hence,
increase in either or both can lead to the development
of hypertension. In order to explore the underlying
mechanism of action, the plant extract was studied in
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Figure 2 The concentration-response curves showing inhibitory
effect of (A) Viola odorata crude extract (Vo.Cr) and (B)
verapamil on force and rate of contraction of isolated guinea-
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Siddiqi et al. Lipids in Health and Disease 2012, 11:6
http://www.lipidworld.com/content/11/1/6
Page 6 of 12
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
0.03 0.3 3
PE (1μM) E-denuded
K+ (80 mM)
PE (1μM) + L-NAME E-intact
PE (1μM) E-intact
10
Baseline E-intact
Baseline E-denuded
Baseline E-intact + L-NAME
100
50
0
50
100
(A)
* *** ***
* * *
*
**
***
[Vo.Cr] mg/ml
%
 re
la
xa
tio
n 
   
%
 o
f P
E 
(1
μ
M
)
0.003 0.03 0.3 3
PE (1μM) E-intact
100
50
0
50
100
Baseline
(B)
PE (1μM) E-denuded
K+ (80 mM)
[Verapamil] μM
%
 re
la
xa
tio
n 
  %
 o
f P
E 
 (1
μ
M
)
-4.5 -4.0 -3.5 -3.0 -2.5 -2.0
0
25
50
75
100 Control
Vo.Cr (0.03 mg/ml)
Vo.Cr (0.1 mg/ml)
(C)
***
***
Log [Ca++] M
%
 o
f C
on
tro
l m
ax
im
um
-4.5 -4.0 -3.5 -3.0 -2.5 -2.0
0
25
50
75
100 Control
Verapamil (0.03μM)
Verapamil (0.01μM)
(D)
***
***
 Log [Ca++] M
%
 o
f C
on
tro
l m
ax
im
um
Figure 3 (A) Effect of Viola odorata crude extract (Vo.Cr) and (B) verapamil on baseline tension and on high K+ and phenlyephrine
(PE)-induced contractions in the absence and presence of L-NAME in endothelium (E)- intact and E-denuded isolated rat aortic
preparations. The responses on baseline are expressed as a percentage of PE-induced contraction. (C) The concentration-response curves of Ca+
+ in the absence and presence of increasing concentrations of Vo.Cr and (D) verapamil in isolated rat aortic preparations. Values shown are
mean ± SEM; n = 4-7. In (A) and (B), *P < 0.05, ** P < 0.01 and *** P < 0.001 represent comparison of responses on E- intact preparations in the
absence vs. presence of L-NAME (Student’s t-test). In (C) and (D), *** P < 0.001 shows a comparison with control maximum (Two way ANOVA
followed by Bonferroni’s post-test correction).
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isolated guinea-pig atria and rat aortic preparations. In
guinea-pig right atria, the crude extract showed negative
inotropic and chronotropic effects, similar to that
caused by verapamil, a standard Ca++ antagonist [27],
which is known to cause cardiac depression through the
inhibition of the slow inward current during the action
potential plateau [28]. This indicates that the observed
cardiac inhibitory effect of the plant extract might be
causing a decrease in cardiac output and ultimately a
fall in the blood pressure.
To characterize the vasodilator effect, when tested in
pre-contracted rat aortic preparations, the plant extract
inhibited both high K+ (80 mM) and PE (1 μM)-induced
vasoconstriction. Influx of extracellular Ca++ through
voltage-dependent channels (VDCs) and receptor-oper-
ated channels (ROCs) is caused by high K+ and PE,
respectively, resulting in increased intracellular Ca++
which causes contraction [20]. This shows that the plant
extract has the ability to block Ca++ influx through both
VDCs and ROCs. The Ca++ channel blocking (CCB)
activity of the crude extract was further confirmed when
it shifted the Ca++ concentration-response curves
(CRCs) to the right with the suppression of maximum
response. Verapamil, a standard CCB used clinically [29]
also caused a rightward shift of the Ca++ CRCs in a
dose-dependent manner.
In addition to VDCs and ROCs, there is another
mechanism of contraction in which Ca++ influx into the
cell is guided through the Ca++ release from the internal
stores of inositol-1, 4, 5-trisphosphate (IP3)-sensitive sar-
coplasmic reticulum [30]. When the control responses
of PE were taken in Ca++ free medium, the crude
extract in increasing concentrations inhibited the PE-
induced peaks, indicating that it is also acting through
inhibition of the intracellular Ca++ channels. The results
were similar to that of verapamil, suggesting the pre-
sence of CCB-like activity in the plant extract which
might be responsible for its cardiac inhibitory effect in
atrial preparation and the blood pressure lowering effect
in anaesthetized rats though additional mechanism can-
not be ruled out.
The vasodilator effect of the crude extract was further
studied in isolated rat aortic preparations for its effect
on vascular preparations with intact endothelium. The
results showed that vasodilatation caused by Vo.Cr was
reduced when the endothelium was removed, indicating
some role of endothelium-dependent vasodilator
mechanisms. There is a strong evidence that endothe-
lium-derived relaxing factor (EDRF) [31] is nitric oxide
(NO) synthesized in the endothelium by nitric oxide
synthase (NOS) from L-arginine [32]. In order to further
study the endothelium-dependent component of the
crude extract, when the aortic rings with intact endothe-
lium were pretreated with L-NAME, an inhibitor of
NOS [33], the vasodilator effect was partially inhibited.
The degree of relaxation induced by Vo.Cr was almost
superimposable on that observed in endothelium-
denuded preparations, indicating that the endothelium-
dependent relaxation was through NO-dependent path-
ways. When the relaxant effect of the plant extract was
further studied in the presence of atropine, pyrilamine
and methysergide, it was found insensitive showing that
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Figure 4 Bar charts showing the inhibitory effects of (A) the
crude extract of Viola odorata (Vo.Cr) and (B) verapamil on
phenlyephrine responses in Ca++ free Kreb’s solution in
isolated rat aorta preparations. Values shown are mean ± SEM; n
= 4; *** P < 0.001; one way ANOVA (Tukey’s multiple comparison).
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the vasodilator effect of the plant extract did not involve
muscarinic, histaminergic [34] or serotonergic receptors
[35] respectively, which are known to have a role in
receptor-mediated NO release from the endothelium
(data not shown). Thus, these results indicate the invol-
vement of other possible NO-dependent pathway(s) like
the direct release of NO from the endothelial cells [36].
When the extract was tested on resting tension of
endothelium-intact and denuded rat aortic rings, it
caused a concentration-dependent vasoconstrictor effect.
The maximum contractile effect was achieved at the
concentration of 3 mg/ml which was significantly
greater in the denuded tissues as compared to that in
the intact ones. This again indicates the role of endothe-
lium-derived NO which might have hindered the full
expression of contractile effect as it is a potent vasodila-
tor. When the vasoconstrictor effect of the plant extract
in intact tissues was reproduced in the presence of L-
NAME, the effect was augmented reaching similar to
that in the denuded tissues which is in line with our
findings regarding the vasodilator effect. The vasocon-
strictor effect of Vo.Cr was completely blocked in intact
and denuded aortic preparations when reproduced in
the tissues pretreated with phentolamine, a standard a-
adrenergic antagonist (data not shown). Despite the
observed vasoconstrictor effect in the vascular
Table 1 Effect of Viola odorata (Vo.Cr) on serum total cholesterol and triglycerides in rats treated with tyloxapol.
Groups Total cholesterol
(mg/100 ml)
Triglycerides
(mg/100 ml)
Control saline 10 ml/kg; i.p.
(n = 6)
58.26 ± 2.83 55.21 ± 4.72
Tyloxapol 500 mg/kg; i.p.
(n = 6)
621.3 ± 24.82$$$ 5134 ± 451.8$$$
Tyloxapol 500 mg/kg; i.p. + Atorvastatin 10 mg/kg
(n = 6)
368.2 ± 58.85*** 3100 ± 297.0**
Tyloxapol 500 mg/kg; i.p. + Vo.Cr 150 mg/kg
(n = 6)
495.3 ± 18.82 3841 ± 599.4
Tyloxapol 500 mg/kg; i.p.+ Vo.Cr 300 mg/kg
(n = 6)
405.1 ± 50.33** 3068 ± 218.8**
Tyloxapol 500 mg/kg; i.p.+ Vo.Cr 600 mg/kg
(n = 6)
351.9 ± 23.21*** 2985 ± 232.1**
Values shown are mean ± SEM, n = 6
$$$ P < 0.001; compared with normal controls.
** P < 0.01; *** P < 0.001 compared with tyloxapol controls.
(One way ANOVA followed by Tukey’s post-test)
(ANOVA: analysis of variance; i.p. intraperitoneal)
Table 2 Effect of Viola odorata (Vo.Cr) on serum lipids, glucose, diet consumption and body weight in rats fed on
atherogenic diet.
Parameters Normal diet
(n = 7)
Atherogenic diet
(n = 8)
Atherogenic +
Atorvastatin
10 mg/kg
(n = 6)
Atherogenic + Vo.Cr
300 mg/kg
(n = 7)
Atherogenic
+ Vo.Cr
600 mg/kg
(n = 8)
Total cholesterol
(mg/100 ml)
76.29 ± 5.67 295 ± 27.37$$$ 129.7 ± 9.70*** 211.7 ± 12.83* 140.3 ± 14.58***
HDL-C (mg/100 ml) 29.94 ± 2.70 18.10 ± 0.89$$$ 27.06 ± 1.83* 15.35 ± 1.96 26.07 ± 1.71*
LDL-C (mg/100 ml) 31.91 ± 5.71 259.5 ± 27.4$$$ 87.41 ± 8.88*** 180.5 ± 12.43* 99.50 ± 14.25***
Triglycerides
(mg/100 ml)
72.25 ± 4.41 86.36 ± 3.69 76.31 ± 5.82 78.99 ± 4.17 73.71 ± 2.16
Atherogenic index 1.68 ± 0.31 15.71 ± 2.01$$$ 2.19 ± 0.76*** 13.92 ± 1.65 4.49 ± 0.55***
Glucose (mg/100 ml) 107.4 ± 5.74 86.77 ± 6.42 113.8 ± 3.68 109.7 ± 5.68 106.8 ± 5.67
Diet consumption g/day/kg 129.4 ± 6.28 115.9 ± 3.74 101.2 ± 4.35 100.3 ± 3.15 97.58 ± 2.56*
% change in body weight 29.13 ± 2.19 44.05 ± 1.90$$$ 34.74 ± 2.09* 34.97 ± 1.54* 33.49 ± 1.60**
Abbreviations: ANOVA: analysis of variance; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.
Values shown are mean ± SEM, n = 6-8
$$$ P < 0.001 compared with normal controls
* P < 0.05; ** P < 0.01; *** P < 0.001 compared with atherogenic controls.
(One way ANOVA followed by Tukey’s post-test)
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preparation, the plant extract did not show any hyper-
tensive effect in the intact animal, which could probably
be due to some of the endogenous mediators in the
whole body blocking this vasoconstrictor effect. Alterna-
tively, the combined presence of the strong vasodilator
and cardio suppressant components in the plant extract
is not letting the extract to express its vasoconstrictor
component in terms of an increase in the blood pres-
sure. Whatever might be the reason, the vasoconstrictor
element of the plant extract does not seem to be of any
clinical significance, while evaluating its antihypertensive
effect. This study is also in line with the earlier reports
on Acorus calamus [37] and Orchis mascula [38] posses-
sing a combination of vasoconstrictor and vasodilator
components without showing any hypertensive activity
when tested in intact animals.
Interestingly, plant extract also caused antidyslipi-
demic effect. In order to study the possible mode of
action of the lipid-lowering activity of the plant, two dif-
ferent models were used. Tyloxapol-induced dyslipide-
mia is a widely used model to explore possible
mechanism of lipid lowering drugs. It causes drastic
increase in serum triglycerides and cholesterol levels
due to increase in hepatic cholesterol synthesis particu-
larly by the increase in HMG Co-A reductase (3-
hydroxy-3-methyl-glutaryl Co-A reductase) activity [39]
and by the inhibition of lipoprotein lipase responsible
for hydrolysis of plasma lipids [40]. The plant extract
caused a significant inhibition in the rise of serum tri-
glycerides and cholesterol level, which indicates that
inhibition of lipid biosynthesis, might be the possible
mechanism of its lipid-lowering action.
The atherogenic or high-fat diet-induced dyslipidemia
model induces a marked increase in serum total choles-
terol (TC), low density lipoprotein-cholesterol (LDL-C)
and atherogenic index by enhancing intestinal absorp-
tion and secretion, and decreasing catabolism of choles-
terol [41]. It caused a decrease in high density
lipoprotein-cholesterol (HDL-C) but did not affect
serum triglyceride (TG). Treatment of the rats receiving
atherogenic diet with the extract caused a significant
decrease in TC and LDL-C while increased HDL-C
without effecting TG and glucose levels. This may be
attributed to the presence of phytochemical constituents
like flavanoids and saponins in the plant. Flavanoids are
reported to lower LDL-C and increase HDL-C concen-
trations in hypercholesteremic animals [42]. Saponins
have shown to inhibit pancreatic lipase activity in high
fat diet fed mice leading to greater fat excretion due to
reduced intestinal absorption of dietary fats [43]. The
plant extract also markedly reduced atherogenic index
which is considered a better indicator of coronary heart
disease risk than individual lipoprotein concentration
[44]. The lipid lowering potential of the plant extract
was comparable with that of atorvastatin which was
used as a positive control in this study and is well
known lipid-lowering drug acting via inhibition of HMG
Co-A reductase [45].
Atherogenic diet also causes oxidative stress (enzy-
matic and non-enzymatic) in rats. It therefore increases
oxidation of LDL-C which plays a key role in genesis of
atherosclerosis. Antioxidants are known to effectively
prevent this kind of cellular damage [46]. The presence
of strong antioxidant activity in the extract [10] may
offer additional benefit against oxidative stress caused by
high cholesterol.
There was a significant increase in the body weights of
rats on atherogenic diet compared to control group. The
gain in the body weight leading to obesity is an obvious
effect of such high fat diets intake [47]. It is worth men-
tioning that in addition to the beneficial effects of Vo.Cr
in hypertension and dyslipidemia, it significantly
reduced the body weight, via reducing diet intake, bring-
ing close to the body weights of normal diet-fed rats,
thus showing the weight-reducing potential of the plant
extract. Obesity is amongst major health issues predis-
posing people to metabolic diseases such as hyperten-
sion and diabetes. According to WHO, by 2015, 2.3
billion human adults would be overweight while 700
million are expected to be obese [48]. There is poor
compliance with conventional weight-management pro-
grams of increasing energy expenditure via physical
activity while the drug treatment is often associated
with rebound weight gain after the cessation of respec-
tive drug therapy [49]. In recent times, evaluation of
therapeutic options from natural sources for treating
obesity (one of the factors involved in the development
of metabolic syndrome), are the focus of interest
[50,51]. In this study, apparently, there was no effect on
normal blood glucose level which does not rule out its
potential as an anti-diabetic agent, and further studies
on diabetic models are required. The antihypertensive,
cardio-suppressor, vasodilator, antidyslipidemic and
weight reducing properties of Vo.Cr strongly attest its
usefulness in metabolic syndrome particularly if it was
shown to possess anti-diabetic activity. Natural products
of similar pharmacological profile are widely used in the
management of metabolic syndrome [52,53].
Conclusions
In summary, the results of this study show that the
crude extract of leaves of Viola odorata exhibited blood
pressure-lowering effect in rats under anaesthesia. In the
isolated tissue preparations, the extract showed vasore-
laxation mediated through inhibition of Ca++ influx via
membranous Ca++ channels, its release from intracellu-
lar stores and NO-mediated pathways, which possibly
explain the fall in BP. The plant also showed reduction
Siddiqi et al. Lipids in Health and Disease 2012, 11:6
http://www.lipidworld.com/content/11/1/6
Page 10 of 12
in body weight and antidyslipidemic effect which may be
due to the inhibition of synthesis and absorption of
lipids and antioxidant activities. Thus, this study pro-
vides a pharmacologic rationale to the medicinal use of
Viola odorata in hypertension and dyslipidemia and
may be a good candidate to be developed as antihyper-
tensive and antidyslipidemic medicine, with therapeutic
potential in obesity and metabolic syndrome.
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